#obesity Archives

First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

by Truveta Research | Nov 27, 2023 | Research, Research Insights

Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro). Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1...

Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends

by Truveta Research | Jun 6, 2023 | Research, Research Insights

Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...

First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

Ozempic, Wegovy, and Mounjaro: On- and off-label prescribing trends

Share this

Recent posts

Follow Truveta

Stay up-to-date

Ready to join us on our mission of Saving Lives with Data?